Evidence map›Paper›PMID 41005567›Full record

ArticleKidney international2026

Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023.

William E Smoyer, Barbara S Gillespie, Louise Oni, Carla Nester, Robert G Nelson, Petter Bjornstad, Hiddo J L Heerspink, Michelle Denburg, Oliver Gross, Jan Marquard and 14 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Pediatric Nephrology in Clinical Practice.Indian journal of pediatrics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

William E SmoyerCenter for Clinical and Translational Research, The Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, USA. Electronic address: William.Smoyer@nationwidechildrens.org.
Barbara S GillespieDivision of Nephrology and Hypertension, University of North Carolina, Chapel Hill, North Carolina, USA; Fortrea Inc, Durham, North Carolina, USA.
Louise OniUniversity College London Centre for Bladder and Kidney Health, Great Ormond Street Hospital for Children, London, United Kingdom; Department of Women's and Children's Health, University of Liverpool, United Kingdom.
Carla NesterDepartment of Pediatrics, Stead Family Children's Hospital, University of Iowa, Iowa City, Iowa, USA.
Robert G NelsonResearch Division, Joslin Diabetes Center, Boston, Massachusetts, USA; Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Petter BjornstadDivision of Endocrinology, Metabolism, and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA; Division of Endocrinology, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA; Seattle Children's Hospital, Seattle, Washington, USA; Seattle Children's Research Institute, Seattle, Washington, USA.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Michelle DenburgDepartment of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Epidemiology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Oliver GrossClinic for Nephrology and Rheumatology, University Medical Center Goettingen, Goettingen, Germany.
Jan MarquardBoehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA.
Dominik SteublBoehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Nephrology, Hospital Rechts der Isar, Technical University Munich, Munich, Germany.
Mark D LimKidney Health Initiative, American Society of Nephrology, Washington, District of Columbia, USA.
Cesia CreightonKidney Health Initiative, American Society of Nephrology, Washington, District of Columbia, USA.
Seyi BalogunKidney Health Initiative, American Society of Nephrology, Washington, District of Columbia, USA.
Lauren EvaNephCure, King of Prussia, Pennsylvania, USA.
Kelly HelmNephCure, King of Prussia, Pennsylvania, USA.
Joshua M TarnoffNephCure, King of Prussia, Pennsylvania, USA.
Shamir TuchmanDivision of Pediatrics and Maternal Health, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Mona KhuranaDivision of Pediatrics and Maternal Health, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Lily MulugetaDivision of Pediatrics and Maternal Health, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Lynne YaoDivision of Pediatrics and Maternal Health, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Kirtida MistryDivision of Cardiology and Nephrology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Aliza ThompsonDivision of Cardiology and Nephrology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Howard TrachtmanDepartment of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: howardtrachtman21@gmail.com.

Funding

Research Project Core 2P50DK114786 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI Razzaghi Hanieh · 2017 to 2026
$9.6M
NIDDK NIH HHS P50 DK114786
6 · The paper itself

Abstract

Pediatric patients with chronic kidney disease (CKD) are treated with nonspecific therapies such as renin-angiotensin-aldosterone system inhibitors; however, there are no approved therapies to slow the progression of pediatric CKD across its diverse etiologies. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated efficacy in slowing the rate of decline in estimated glomerular filtration rate and CKD progression in adults. These therapies hold the promise of similar clinical benefit for pediatric patients with CKD by potentially delaying progression to kidney failure. However, clinical data informing the efficacy, safety, and dosing of these products in pediatric patients with CKD are lacking. To address this issue, a 1.5-day workshop was convened by the Kidney Health Initiative and NephCure, with participation from stakeholders that included regulators, National Institutes of Health representatives, trialists, clinicians and investigators, industry representatives, patient advocates, and caregivers. The goal of the workshop was to elucidate the challenges and strategize approaches to evaluate the use of SGLT2is in pediatric patients with CKD. To this end, presentations and discussions at the workshop focused on the data supporting the degree to which the course of CKD and expected treatment responses between adult and pediatric populations with CKD are similar, and hence, the degree to which, if any, data from the trials of SGLT2is in adults could be extrapolated to pediatric patients with CKD. Discussions also focused on trial design feasibility, end points, gaps in knowledge, and safety considerations for SGLT2is in pediatric CKD. The workshop proposed pathways to advance the evaluation of SGLT2is as therapeutic agents to treat glomerular and nonglomerular pediatric CKD while identifying remaining challenges and research priorities.

Indexed as

Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsChildDisease ProgressionGlomerular Filtration RateHumansKidneySodium-Glucose Transporter 2 Inhibitorschronic kidney diseaseend-stage kidney diseasekidney failurepediatric extrapolationsodium-glucose cotransporter-2 inhibitors

Identifiers

PMID41005567
PMCPMC13440144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.